Mesa Laboratories, Inc. (MLAB)
NASDAQInformation TechnologyMedical - SpecialtiesSnapshot 2026-11-04
$126.19+0.57%
Close 2026-11-04 · 1-day change
NASDAQInformation TechnologyMedical - SpecialtiesSnapshot 2026-11-04
QuarterlyIQ Insights · MLAB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 249.7 | 249.1 | 241.0 | 216.2 | 219.1 | 184.3 | 133.9 | 117.7 | 103.1 | 96.2 | 93.7 | 84.7 | 71.3 | 52.7 | 46.4 | 39.6 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 96.2 | 93.7 | 84.7 | 71.3 | 52.7 | 46.4 | 39.6 |
| Cost of Revenues | 89.4 | 90.9 | 90.1 | 82.9 | 85.4 | 75.2 | 46.9 | 52.3 | 42.2 | 41.6 | 40.4 | 33.2 | 27.9 | 21.0 | — | 16.1 |
| Gross Profit | 160.3 | 158.3 | 150.9 | 133.3 | 133.7 | 109.1 | 87.0 | 65.4 | 60.9 | 54.6 | 53.2 | 51.4 | 43.4 | 31.7 | 28.9 | 23.5 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 20.0 | 20.3 | 19.5 | 19.3 | 20.5 | 15.8 | 10.4 | 6.4 | 3.5 | 3.5 | 4.2 | 4.0 | 3.3 | 2.3 | 2.0 | 1.4 |
| Operating Income | 22.5 | 18.5 | 16.3 | (272.1) | 3.3 | 4.7 | 12.4 | 7.9 | 9.8 | 2.2 | 16.3 | 16.3 | 15.9 | 11.8 | 13.1 | 12.5 |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 10.7 | 11.9 | 5.7 | 4.8 | 3.9 | 8.0 | 5.5 | — | — | — | — | — | — | — | — |
| Interest & Investment Income | — | — | — | — | — | — | 0.1 | 1.0 | — | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | — | — | — | 7.9 | 4.5 | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (13.1) | (6.5) | (10.4) | (3.6) | (3.7) | (1.1) | (10.1) | (4.1) | — | — | — | — | — | — | — | (0.1) |
| Asset Writedown | — | — | — | — | — | — | 0.0 | 0.3 | 4.8 | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 9.4 | 12.0 | 6.0 | (275.6) | (0.4) | 3.6 | 2.3 | 3.9 | 8.6 | 0.3 | 14.3 | 15.6 | 15.3 | 13.1 | 13.0 | 12.3 |
| Income Tax Expense | 4.6 | 5.3 | 7.9 | (21.4) | (1.3) | 1.7 | (1.0) | 2.1 | 1.1 | 3.3 | 3.1 | 4.4 | 5.8 | 4.1 | 4.5 | 4.4 |
| Net Income | ||||||||||||||||
| Net Income | 4.8 | 6.7 | (2.0) | (254.2) | 0.9 | 1.9 | 3.3 | 1.8 | 7.5 | (3.0) | 11.2 | 11.2 | 9.6 | 9.0 | 8.5 | 7.9 |
| Per Share | ||||||||||||||||
| Basic EPS | 0.85 | 1.22 | (0.36) | (47.20) | 0.17 | 0.36 | 0.66 | 0.42 | 1.95 | (0.79) | 3.04 | 3.10 | 2.72 | 2.61 | 2.52 | 2.41 |
| Diluted EPS | 0.83 | 1.21 | (0.36) | (47.20) | 0.17 | 0.35 | 0.64 | 0.41 | 1.86 | (0.79) | 2.91 | 2.97 | 2.63 | 2.49 | 2.35 | 2.29 |
| Revenue per Share | 43.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 5.7 | 5.5 | 5.4 | 5.4 | 5.3 | 5.2 | 5.0 | 4.2 | 3.8 | 3.8 | 3.7 | 3.6 | 3.5 | 3.4 | 3.4 | 3.3 |
| Diluted Weighted Avg Shares | 5.8 | 5.6 | 5.4 | 5.4 | 5.4 | 5.3 | 5.1 | 4.4 | 4.0 | 3.8 | 3.8 | 3.8 | 3.7 | 3.6 | 3.6 | 3.5 |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | 37.1 | 29.8 | 30.0 | 20.9 | 19.2 | 11.7 | 25.1 | 23.5 | 21.5 | 15.6 | 16.5 | 14.7 |
| EBIT | 22.5 | 18.5 | 16.3 | (272.1) | 3.3 | 4.7 | 12.4 | 7.9 | 9.8 | 2.2 | 16.3 | 16.3 | 15.9 | 11.8 | 13.1 | 12.5 |
| Effective Tax Rate | 48.7% | — | — | — | 339.1% | 47.6% | -42.2% | 54.0% | 13.2% | 1084.1% | 21.8% | 28.2% | 37.6% | 31.3% | 34.9% | 35.8% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.